GlassScriptPhysician profile
Dinesh Parmar
NPI 1821084534
$1,733.85
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $328 · 2021: $211 · 2022: $560 · 2024: $15.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $228.43 | 2019-2022 | |
| Genzyme Corporation | $166.10 | 2019-2022 | |
| Pfizer INC. | $128.27 | 2019-2021 | |
| Sobi, INC | $118.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $83.88 | 2019-2022 | |
| Partner Therapeutics, INC. | $78.82 | 2019-2020 | |
| Exelixis INC. | $76.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.94 | 2019-2021 | |
| Daiichi Sankyo INC. | $62.29 | 2019-2020 | |
| Seagen INC. | $56.93 | 2020-2022 | |
| Tesaro, INC. | $52.57 | 2019 | |
| Incyte Corporation | $48.68 | 2020-2021 | |
| Coherus Oncology, INC. | $47.69 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $41.62 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $39.74 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $37.61 | 2021 | |
| Celgene Corporation | $35.96 | 2019-2022 | |
| Lilly USA, LLC | $34.88 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.20 | 2019 | |
| Janssen Scientific Affairs, LLC | $31.38 | 2020 | |
| Eisai INC. | $22.49 | 2020 | |
| Deciphera Pharmaceuticals INC. | $21.38 | 2021 | |
| Karyopharm Therapeutics INC. | $16.73 | 2020 | |
| Myovant Sciences INC. | $15.86 | 2022 | |
| Global Blood Therapeutics, INC. | $15.53 | 2022 | |
| Puma Biotechnology, INC. | $15.41 | 2020 | |
| Aveo Pharmaceuticals, INC. | $15.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.39 | 2019 | |
| Amgen INC. | $12.50 | 2019 | |
| Emd Serono, INC. | $12.33 | 2020 | |
| Secura Bio, INC. | $3.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.